In vasive p u lm o n ary aspe rgillo sis, a le a d in g cause of m orbidity a n d m o rtality in patien ts w ith acute leuke m ia, is difficult to d ia g n o se a ntem orte m because its sign s a n d sy m p to m s are ill-defined. To refine the clinical description of this infection, w e review ed our experience w ith 15 p ath o lo g ic a lly docum ented cases of invasive p u lm o n a ry a sp e rgillo sis in a p opu lation of 60 p atients treated for acute leukem ia. F in din gs oc curring sign ific a n tly m ore often ( P < .001) a m o n g cases than controls included pleuritic chest pain; acute sinus tenderness, a n d n a sa l discharge, e p istaxis a n d eschar; rales; de velo p m e n t of m u ltilo b ar in fil trates after the 14th h o sp ita l d ay; a n d presence of nodu lar or cavitary infiltrates. In addition , patien ts w ith in vasive p u lm o n a ry a sp e rgillo sis h a d a sig n ifi cantly p rolon ged du ration of gra n u lo cy to p e n ia , more febrile d a y s a n d febrile episodes w ithou t a fever 
In vasive p u lm o n ary aspe rgillo sis, a le a d in g cause of m orbidity a n d m o rtality in patien ts w ith acute leuke m ia, is difficult to d ia g n o se a ntem orte m because its sign s a n d sy m p to m s are ill-defined. To refine the clinical description of this infection, w e review ed our experience w ith 15 p ath o lo g ic a lly docum ented cases of invasive p u lm o n a ry a sp e rgillo sis in a p opu lation of 60 p atients treated for acute leukem ia. F in din gs oc curring sign ific a n tly m ore often ( P < .001) a m o n g cases than controls included pleuritic chest pain; acute sinus tenderness, a n d n a sa l discharge, e p istaxis a n d eschar; rales; de velo p m e n t of m u ltilo b ar in fil trates after the 14th h o sp ita l d ay; a n d presence of nodu lar or cavitary infiltrates. In addition , patien ts w ith in vasive p u lm o n a ry a sp e rgillo sis h a d a sig n ifi cantly p rolon ged du ration of gra n u lo cy to p e n ia , more febrile d a y s a n d febrile episodes w ithou t a fever d i a gn o sis a n d U N TIL R E C E N T L Y , invasive pulm onary aspergillosis was a uniform ly fatal disease in patients with acute leu k em ia.1-3 Som e patients now survive this infection when it is diagnosed and treated early, especially if the leukem ia en ters rem ission. 4 5 H ow ever, the diagnosis o f inva sive pulm onary aspergillosis is difficult to estab lish antem ortem ,6'7 and even in recent series, 43% to 100% o f cases have been detected only at necropsy. [8] [9] Previous case series1-46 7 have identified nu merous clinical findings associated with invasive pulm onary aspergillosis. B eing uncontrolled, these studies have been lim ited to an analysis o f the presence o r absence o f such findings. In par ticular, they do not perm it distinction o f those clinical features specific to invasive pulm onary aspergillosis from those com m on to patients hos pitalized for treatm ent o f acute leukem ia. Fur therm ore, the duration o f som e clinical varia bles, rather than their m ere presence, m ay be an important discrim inating factor. Exam ples in clude duration o f granulocytopenia, fever, and antibiotic e x p o su re.10 For these reasons, the exact clinical characteristics o f invasive pulm o nary aspergillosis rem ain ill-defined, im pairing the phy sician 's ability to recognize this disease antem ortem .
T o im prove o u r understanding o f the clinical features o f invasive pulm onary aspergillosis, we perform ed a case-control study. O ur intent was to identify and quantitate those clinical findings that characterize invasive pulm onary aspergillo sis in patients with acute leukem ia. O ur observa tions should facilitate earlier antem ortem diagno sis of invasive pulm onary aspergillosis in these patients.
METHODS

Patient Population
The study group consisted o f 65 patients treated in the O ncol ogy Study Unit o f the Hospital o f the University o f Pennsylvania (Philadelphia) between July 1, 1978, and Ja n 3 1 , 1981, for acute myelogenous leukemia (A M L ), acute lymphocytic leukem ia (ALL), or blast crisis of chronic m yelogenous leukem ia (CM L-BC) . An analysis o f risk factors for invasive pulm onary aspergil losis in these patients has been published previously." Induc tion therapy for AM L consisted o f daunorubicin and cytosine arabinoside, with or without 6-thioguanine (DAT or DA). Re-lapses were treated with the com bination o f cyclophospham ide, vincristine, cytosine arabinoside, and prednisone (CO A P), or with 5-azacytidine, V P -16 (etoposide), or m-AM SA. Induction therapy for ALL was daunorubicin, vincristine, and prednisone (DVP) followed by com binations of m ethotrexate and L-aspara ginase and/or CO A P. CM L in blast crisis was usually treated with hydroxyurea, or vincristine and prednisone, but occasion ally induction chem otherapy (DAT) was used.
Cultures of the throat, stool, and urine were obtained on admission. T hereafter, bacterial and fungal cultures o f these sites and of blood were obtained at the onset of fever and repeat ed as clinically indicated. If a pulm onary infiltrate developed for which a diagnosis was not apparent, bronchoscopy with brushings, washings and, if possible, transbronchial biopsy was per formed, followed by fine needle biopsy o f the lung or open lung biopsy, if necessary. During the study period, am photericin B was not adm inistered routinely to patients with fever o f uncer tain origin.
A case was defined as a patient who developed pathologically documented evidence o f invasive pulm onary aspergillosis (in cluding surgical and autopsy material) while hospitalized in our institution. M icrobiological confirm ation of the pathological di agnosis was not required. Probable and possible cases included patients in whom invasive pulm onary aspergillosis was clinical ly suspected but for whom pathologic confirm ation was lacking. Controls included all other patients in whom the diagnosis of invasive pulmonary aspergillosis was not established or suspect ed. Only adm issions for intense chem otherapy for acute leuke mia were evaluated.
A single admission was review ed for each patient. For cases, the admission during which invasive pulm onary aspergillosis developed w as chosen. If a control patient had more than one admission for intense chem otherapy, a single admission was randomly selected. These criteria were used to ensure that all patients received sim ilar cytoreductive therapy and were at risk for the granulocytopenia and infection typical o f this therapy.
Fifteen of the 65 patients satisfied the case definition o f inva sive pulmonary aspergillosis. O f these 15, two were diagnosed by open lung biopsy, nine by postm ortem exam ination (four confirmed by culture), two by bronchoscopic biopsy, one by bronchial washings, brushings, and culture, and one by bronchi al cytology and culture. Tw o cases had concurrent sinus histopathology and culture, and three had positive nasal cultures. O f the 11 cases with culture confirm ation, ten had Aspergillus flavus and one A niger. Five patients with either probable or possi ble invasive pulmonary aspergillosis were identified Because a diagnosis had not been established, they were excluded from analysis. Three of the five had undiagnosed pulm onary infil trates during prolonged febrile episodes. O f these, two died and did not have an autopsy while the others went on to an allogeneic bone marrow transplant com plicated by invasive pulmonary' aspergillosis. A fourth undiagnosed, probable case had nasal symptoms at our institution that also resolved before allogeneic bone marrow transplantation at another institution. This trans plantation was also com plicated by nasal invasive aspergillosis. The fifth excluded patient had a prolonged fever and a urine isolate of Aspergillus species but had no confirm ation o f an infection and no autopsy. The rem aining 45 patients served as controls. None o f these patients had m icrobiological or patho logic evidence o f invasive pulm onary aspergillosis, although some had evidence of esophageal or systemic candidiasis, and others had prolonged fevers without a clear origin. Patients were not matched for type of leukem ia or chem otherapy regimen(s) received. Twenty autopsies were perform ed (nine cases and 11 controls); all autopsy protocols were reviewed.
A febrile episode was defined as the presence of any recorded oral or axillary temperature a 100 °F on two or more consecutive days. A febrile episode was considered to have a definite source if any of the following were documented: (1) a blood culture positive for an organism thought not to be a contam inant: (2) a physical finding such as perirectal cellulitis or abscess, perio dontal cellulitis or abscess, soft-tissue cellulitis, or esophagitis; (3) a fourfold viral titer increase or positive viral culture and an associated clinically consistent syndrom e; or (4) a drug fever or transfusion reaction. A febrile patient who developed a pulm o nary infiltrate that was not diagnosed pathologically or microbiologically was considered to have a fever without a diagnosed source.
Data Analysis
Sixty-two variables were evaluated. O f these, eight were thought a priori to be the clinical characteristics most likely to identify patients with invasive pulm onary aspergillosis and were analyzed in greatest detail. These were pleuritic p a in ,12 nasal and sinus disease,10 duration o f fever,2,5 fever lacking a diag nosed source,5,6 multiple pulm onary infiltrates,512 13 nodular ity and cavitation of the infiltrates,1114 and granulocytopenia ( < 500//uL).810 The Student's / test was used to analyze con tinuous variables and either the chi-square or Fisher's exact test to analyze discrete variables. All tests were two-tailed. A differ ence was considered to be statistically significant when the P value was < .0 5 . Curves depicting the duration of granulocyto penia and the duration of fever while on antibiotics were calcu lated as Kaplan-M eier plots.
RESULTS
Cases and controls did not differ significantly in age, sex, and hem atologic diagnosis (Table 1) . There was a low com plete rem ission rate in both controls and cases, in part because 18 controls (40%) and nine cases (60% ) w ere in relapse at the time the patients were studied. Nine o f ten cases who died had an autopsy com pared to 11 of 14 controls, indicating that the autopsy rate did not influence case identification. Four (27% ) of the patients who had invasive pulm onary asper gillosis were successfully treated and survived for longer than two m onths. The duration o f hos pitalization was significantly longer in cases (45.7 ± 12.6 days [mean ± SD]) than in con trols (27.8 ± 12.7 days, P < .0005), which reflects the more com plicated and protracted course o f cases. Seven o f the 15 cases had an antem ortem diagnosis o f invasive pulm onary aspergillosis. Patients with 3 or more findings 0 ( 0 ) 6 (60) P < .0004 *N um ber and percentage (in parenthesis) of evaluable patients. tSinus symptoms: stuffiness, discharge, pain, epistaxis. Nine controls were excluded from the analysis since presence or absence of symptoms was not noted.
Sinus/nasal findings included three or more of the following: discharge, epistaxis, ulceration, eschar or tenderness. Seven controls and five cases were excluded since presence or absence of nasal findings was not noted.
§ P > .05.
pain was often but not alw ays contiguous with the infiltrate. Tw o other pulm onary findings, rales in the absence o f congestive heart failure and cough, were m ore com m on in cases than controls. M as sive hem optysis ( > 3 0 0 m L o f blood within a 24-hour period) developed in three patients with in vasive pulm onary aspergillosis, all o f whom had normal clotting factor levels and platelet counts >50,000/yxL as w ell as in tw o controls with dis sem inated intravascular coagulation. Three or more nasal and sinus abnorm alities were only found in cases ( P < .0004). These abnorm alities included nasal ulceration or eschar, epistaxis, and discharge and localized sinus tenderness. O f the six cases with these findings, five ultim ately had either pathologic or m icrobiological evi dence of nasal or sinus aspergillosis. No control had eschar form ation. The num ber o f patients who had isolated sinus tenderness, discharge or epistaxis was not significantly different in the two groups.
All cases and 91% o f controls w ere febrile during hospitalization. The clinical aspects of fever are described in T able 3. T w elve (80% ) of the 15 cases were febrile on adm ission com pared with 21 (47% ) of 45 controls. C ases had a greater num ber o f total febrile days, a greater num ber of febrile days on antibacterial antibiotics, and a greater num ber o f febrile days w ithout a diag nosed source. In addition, febrile episodes w ith out a diagnosis occurred m ore frequently in cases than controls.
The percentage o f patients in the two groups with bacteremic episodes was not different. The incidence o f Candida species infections was also similar, and its presence did not significantly influence the duration o f fever on antibiotics in either group. The proportion o f patients rem ain ing febrile as a function o f days when receiving antibiotics is shown in Fig 1. All cases had at least 14 days o f fever on antibiotics. By the 20th day of antibiotic therapy only 18% o f controls remained febrile com pared with 73% o f cases.
All cases and 78% o f controls developed an abnormal chest x-ray result ( Table 4) . H ow ever, cases developed their first chest x-ray abnorm al ity significantly later in the hospital course than did controls. The initial roentgenographic m ani festations o f the infiltrates o f invasive pulm onary aspergillosis in the cases w ere subtle. In eight cases, the radiologist noted the actual onset of the infiltrate only in retrospect, with an average de lay o f 5.4 days. Bilateral infiltrates were found significantly m ore often in cases than in controls, and in cases progressed to nodularity in 80% and cavitation in 47% . By com parison, only four controls developed pulm onary nodules, none of which cavitated. These nodular lesions were caused by septic pulm onary em boli (two pa tients), pulm onary throm boem bolism (one pa tient), and candidal pneum onia (one patient). dida species pneum onia (one patient), and viral pneum onia (one patient). The total duration o f granulocytopenia was significantly longer in cases than in controls (35.2 ± 12.2 days v 18.8 ±11.0 days, P < .0005, Fig 2) . Less than 20% o f controls re mained granulocytopenic for m ore than 24 days, com pared to 80% o f cases. D ata analysis show ed that the observed differences betw een cases and controls could not be explained by num ber o f chem otherapy cycles adm inistered, type o f ch e m otherapy, persistence o f leukem ia, o r antibiotic class adm inistered. The diagnosis o f the rem aining 21 controls with a pulm onary infiltrate w ere as follow s: bacterial pneum onia (five patients), presum ed bacterial pneum onia (ten patients), hem orrhage (two pa tients), interstitial edem a (tw o patients), Can-
DISCUSSION
Recognition of invasive pulm onary aspergillo sis com plicating therapy for acute leukem ia re mains difficult, in part because its clinical ch ar acteristics have been ill-defined. Previous efforts to characterize this infection1 3'6-7-915 are inad equate, due either to selective em phasis o f only certain clinical features or to lack o f an appropri ate control group. O ur study w as designed to identify those clinical m anifestations o f invasive pulm onary aspergillosis that differ from the ' Mean ± SD. tNum ber and percentage (in parenthesis) of patients with the finding out of the total number of patients with an abnormal chest x-ray. t P S .05. clinical features com m on to all patients with acute leukem ia undergoing intense cytoreductive chem otherapy.
In our patients w ith invasive pulm onary asper gillosis, early evidence of the disease usually was not appreciated. T hus, pleuritic pain, which others have ascribed to a pulm onary in farct,1316 often preceded evidence o f a pulm onary infil trate, and the infiltrate was overlooked by the radiologist for several days. Patients in our study, prim arily infected with A fla v u s, also evi denced signs o f upper respiratory involvem entnasal eschar or ulceration and sinus tendernessbefore or concurrent w ith signs o f pulm onary involvem ent. Cough and rales frequently preced ed roentgenographic evidence o f disease. W hen pulm onary infiltrates appeared, they w ere usual ly m ulticentric and progressed to nodules and cavity form ation. O f interest, m assive hem opty sis occurred in three cases with norm al coagula tion profiles. This observation has been expand ed by A lbelda et a l17 w ho noted that m assive hem optysis in patients w ith invasive pulm onary aspergillosis is usually not associated with severe throm bocytopenia or coagulation disorders but is more frequent in patients w ho are recovering blood cell counts and have developed a cavity within the pulm onary infiltrate.
O ur patients developed sinopulm onary asper gillosis as opposed to system ic aspergillosis be cause the infecting organism in our institution was A flavus. This organism has a propensity for the sinopulm onary tree 18 and, despite its capacity for vascular invasion, often does not infect m ulti ple organs in the m anner o f A fu m ig a tu s , U1 A flavus has been the m ajor pathogen in other caseclusters o f invasive pulm onary aspergillosis in im m unocom prom ised h o sts.1019-20 On the other hand, at centers experiencing A fu m igatus infec tions, the clinical presentation m ay involve more systemic signs than noted in our series.
We also found that fever which persisted dur ing antibiotic therapy was a m ore reliable index of concurrent fungal disease than sim ply dura tion o f antibiotic therapy. This was true even though another source may have been identified initially. '5 2122 In control patients, the mean dura tion o f fever on antibiotics was 11.5 ± 9.4 days, whereas for cases it was 27.7 ± 11.4 days. The duration o f fever in controls is consistent with that noted in docum ented G ram -negative and polym icrobial bacterem ias.23 N ote, how ever, that the mean duration o f fever on antibiotics in controls was significantly longer than the seven days used as a criterion for em piric use o f am photericin B for presum ed fungal infection in patients with acute leukem ia.15 Thus in our con trol patients, a fever o f seven d ay s' duration was not a sensitive sign o f fungal disease.
H alf o f the patients in our study group who remained granulocytopenic beyond the 24th hos pital day developed invasive pulm onary aspergil losis. To determ ine w hether or not this observa tion could be explained by the underlying status of leukem ia, type o f therapy and drug exposure, we undertook a detailed analysis o f granulocyto penia. As we have rep o rted ," granulocytopenia was an independent risk factor for invasive pul monary aspergillosis. Thus, patients undergoing the first induction course o f chem otherapy who experienced prolonged granulocytopenia were at greater risk than a patient w ith m ultiple relapses, febrile episodes, and exposures to antibiotics but with a brief period o f granulocytopenia. W ith recovery o f im m unocom petence24 and o f granu locytes and m onocytes,25 overt fungal super infection is less likely,26 as dem onstrated in experim ental m odels.27 28 Thus, duration o f gran ulocytopenia is an im portant risk factor for inva sive pulm onary aspergillosis.
In certain circum stances, the clinical diagnosis o f invasive pulm onary aspergillosis m ay require a prolonged period o f observation. Indeed, m ost o f our patients developed invasive aspergillosis late in the hospital course. In these patients, signs and sym ptom s developed in an indolent m anner. The presence o f prolonged fever, prolonged granulocytopenia, and a late-appearing infiltrate were helpful clues to the diagnosis. These findings are useful prospectively as well as retrospectively. Patients w ith periods o f fever and granulocytopenia that extend well beyond the mean period for all patients should be consid ered at risk for having invasive pulm onary asper gillosis. Even though this will identify patients at risk com paratively late in the hospital course, it may still identify patients before they are clini cally recognized as having an invasive fungal infection.
These findings can assist the physician caring for patients undergoing chem otherapy for acute leukem ia because they establish a w ell-defined profile o f the clinical characteristics o f invasive pulm onary aspergillosis. Since the m ajority of patients with this infection are only recognized at postm ortem ,89 this profile may allow m ore p a tients to be diagnosed during life. S pecifically, patients w ith persistent fever and receiving anti biotics during prolonged granulocytopenia should be questioned daily for com plaints of pleuritic pain, cough, nasal discharge, epistaxis, and sinus discom fort. They should have careful exam inations of the chest, nose, and paranasal sinuses. In patients in w hom the suspicion o f invasive aspergillosis is high, nasal cultures m ay be useful confirm atory tests10-29 although routine surveillance cultures o f all hospitalized patients with acute leukem ia are not cost-effective in our experience.30 N asal ulcerations o r eschars should be biopsied if coagulation param eters perm it. In addition, chest roentgenogram s should be per formed with special attention to subtle, late-ap pearing infiltrates, particularly those w ith a n o d ular appearance or cavitation.
The goal o f this study w as to foster earlier antem ortem diagnosis o f invasive pulm onary aspergillosis, especially those cases due to A flavus. W hen clinicians recognize the characteristic setting and sym ptom com plex earlier they can proceed with diagnostic m odalities such as fiber optic bronchoscopy,31 needle aspiration, or open lung biopsy. In the future, serologic diagnosis may be possible32 if invasive procedures are con traindicated. W hen the diagnosis is considered, em piric adm inistration o f am photericin B m ay be advisable before the diagnosis can be firm ly es tablished. Increased aw areness o f invasive pul monary aspergillosis and o f its presenting m ani festations may reduce overall m orbidity and mortality for patients undergoing treatm ent for acute leukem ia.
